{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:12:36Z","timestamp":1787069556454,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.msard.2021.102750","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T03:56:15Z","timestamp":1611287775000},"page":"102750","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy"],"prefix":"10.1016","volume":"49","author":[{"given":"Yoshiki","family":"Takai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Misu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Akaishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0248-1595","authenticated-orcid":false,"given":"Shuhei","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2021.102750_bib0001","article-title":"Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence","volume":"7","author":"Akaishi","year":"2020","journal-title":"Neurology(R) neuroimmunology & neuroinflammation"},{"issue":"9","key":"10.1016\/j.msard.2021.102750_bib0002","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archneurol.2010.203","article-title":"Neuromyelitis optica treatment: analysis of 36 patients","volume":"67","author":"Bichuetti","year":"2010","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.msard.2021.102750_bib0003","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41598-017-00860-y","article-title":"Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder","volume":"7","author":"Chen","year":"2017","journal-title":"Scientific reports"},{"issue":"1","key":"10.1016\/j.msard.2021.102750_bib0004","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ene.13186","article-title":"Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder","volume":"24","author":"Chen","year":"2017","journal-title":"European journal of neurology: the official journal of the European Federation of Neurological Societies"},{"issue":"7","key":"10.1016\/j.msard.2021.102750_bib0005","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"issue":"10206","key":"10.1016\/j.msard.2021.102750_bib0006","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.msard.2021.102750_bib0007","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1016\/j.msard.2021.102750_bib0008","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458514525870","article-title":"Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2021.102750_bib0009","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jneuroim.2019.04.007","article-title":"Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review","volume":"332","author":"Enriquez","year":"2019","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.msard.2021.102750_bib0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12883-019-1261-2","article-title":"Effectiveness of rituximab in neuromyelitis optica: a meta-analysis","volume":"19","author":"Gao","year":"2019","journal-title":"BMC Neurol"},{"key":"10.1016\/j.msard.2021.102750_bib0011","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.3389\/fimmu.2018.02066","article-title":"Low-Dose Mycophenolate Mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: A Prospective Multicenter Study in South China","volume":"9","author":"Huang","year":"2018","journal-title":"Frontiers in immunology"},{"issue":"11","key":"10.1016\/j.msard.2021.102750_bib0012","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","article-title":"Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder","volume":"71","author":"Huh","year":"2014","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/j.msard.2021.102750_bib0013","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.msard.2021.102750_bib0014","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1352458515587752","article-title":"Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints","volume":"22","author":"Jeong","year":"2016","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.msard.2021.102750_bib0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12883-018-1056-x","article-title":"Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study","volume":"18","author":"Jiao","year":"2018","journal-title":"BMC Neurol"},{"issue":"2","key":"10.1016\/j.msard.2021.102750_bib0016","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00415-012-6692-2","article-title":"Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica","volume":"260","author":"Kageyama","year":"2013","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.msard.2021.102750_bib0017","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/jca.21215","article-title":"Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica","volume":"27","author":"Khatri","year":"2012","journal-title":"Journal of clinical apheresis"},{"issue":"8","key":"10.1016\/j.msard.2021.102750_bib0018","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/jnnp-2012-304774","article-title":"Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies","volume":"84","author":"Kitley","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2021.102750_bib0019","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s13311-015-0400-8","article-title":"Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders","volume":"13","author":"Kleiter","year":"2016","journal-title":"Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics"},{"key":"10.1016\/j.msard.2021.102750_bib0020","article-title":"Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody","volume":"39","author":"Kojima","year":"2019","journal-title":"Multiple sclerosis and related disorders"},{"issue":"4","key":"10.1016\/j.msard.2021.102750_bib0021","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"issue":"9451","key":"10.1016\/j.msard.2021.102750_bib0022","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2021.102750_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102109","article-title":"Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders","volume":"42","author":"Lim","year":"2020","journal-title":"Multiple sclerosis and related disorders"},{"issue":"3","key":"10.1016\/j.msard.2021.102750_bib0024","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.msard.2021.102750_bib0025","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1744-9987.2009.00780.x","article-title":"Intermittent plasmapheresis prevents recurrence in neuromyelitis optica","volume":"13","author":"Miyamoto","year":"2009","journal-title":"Ther Apher Dial"},{"issue":"9","key":"10.1016\/j.msard.2021.102750_bib0026","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.msard.2021.102750_bib0027","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"The New England journal of medicine"},{"issue":"7","key":"10.1016\/j.msard.2021.102750_bib0028","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jocn.2015.01.028","article-title":"Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica","volume":"22","author":"Qiu","year":"2015","journal-title":"Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia"},{"issue":"4","key":"10.1016\/j.msard.2021.102750_bib0029","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00415-019-09649-7","article-title":"Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study","volume":"267","author":"Shi","year":"2020","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.msard.2021.102750_bib0030","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1620\/tjem.210.307","article-title":"Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica","volume":"210","author":"Takahashi","year":"2006","journal-title":"Tohoku J Exp Med"},{"issue":"4","key":"10.1016\/j.msard.2021.102750_bib0031","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/jnnp-2013-305907","article-title":"Autocrine MMP-2\/9 secretion increases the BBB permeability in neuromyelitis optica","volume":"85","author":"Tasaki","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2021.102750_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J Neurol"},{"key":"10.1016\/j.msard.2021.102750_bib0033","article-title":"Sequential intermittent therapeutic plasma exchange: A possible induction and maintenance therapy in the management of adult patients with neuromyelitis optica spectrum disorder","author":"Viswanathan","year":"2020","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.msard.2021.102750_bib0034","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jneuroim.2015.03.021","article-title":"Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica","volume":"282","author":"Viswanathan","year":"2015","journal-title":"J Neuroimmunol"},{"issue":"8","key":"10.1016\/j.msard.2021.102750_bib0035","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/1352458507077189","article-title":"Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.msard.2021.102750_bib0036","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102750_bib0037","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jns.2016.09.035","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study","volume":"370","author":"Xu","year":"2016","journal-title":"J Neurol Sci"},{"issue":"22","key":"10.1016\/j.msard.2021.102750_bib0038","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.msard.2021.102750_bib0039","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jns.2017.12.034","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder","volume":"385","author":"Yang","year":"2018","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.msard.2021.102750_bib0040","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3389\/fimmu.2016.00592","article-title":"Endothelial Response to Glucocorticoids in Inflammatory Diseases","volume":"7","author":"Zielinska","year":"2016","journal-title":"Frontiers in immunology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482100016X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482100016X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:53:25Z","timestamp":1761900805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482100016X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":40,"alternative-id":["S221103482100016X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102750","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102750","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102750"}}